NCT03101982

Brief Summary

Hypothesis of the Study: Based on the presented results, the investigator hypothesises that HBO preserves neurons that are not irreversibly damaged (i.e. severed) during initial trauma, thus enabling regain of their function. The investigator predicts that HBO treatment protects and enhances motor function in initially paralysed regions, including improvement in function of the extremities as well as recovery of urinary bladder control and bowel function. Outline of the Proposed Study: Within a prospective "proof of principle" trial, a total of 100 patients will be included. Fifty patients will be recruited at the Division of Thoracic and Hyperbaric Surgery, Medical University of Graz. In parallel, 50 control patients will be included at the Department of Orthopaedics and Trauma, Paracelsus University Salzburg, Salzburger Landeskliniken (SALK), Austria. Thereby, all patients that are admitted at the Medical University of Graz can be treated and the enrolment of 50 patients into the treatment group can be implemented within the outlined time frame. The active recruitment period is planned for three years. Both HBO treated and control patients will undergo the same surgical and nonsurgical procedures. HBO treatment will be started within 24 hours after the injury. A total of 21 consecutive daily sessions will be applied, followed by routine rehabilitation programmes. By matching control and HBO-treated patients, an evaluation of the treatment effect of HBO is possible. The outcome will be evaluated by implementing the American Spinal Injury Association (ASIA)-scores and magnet resonance (MR) imaging. Additionally, inflammatory and regenerative blood markers will be analysed (neuroendocrine markers/neuro-transmitters: S100beta, Brain Derived Neurotrophic Growth Factor \[BDNF\], Glial Fibrillary Acidic Protein \[GFAP\], Reactive Oxygen Species (ROS), norepinephrine; array of pro- and anti-inflammatory cytokines and chemokines).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Apr 2017

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 22, 2017

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 5, 2017

Completed
13 days until next milestone

Study Start

First participant enrolled

April 18, 2017

Completed
7.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2024

Completed
Last Updated

May 9, 2025

Status Verified

March 1, 2023

Enrollment Period

7.7 years

First QC Date

March 22, 2017

Last Update Submit

May 6, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Improvement of neurological deficits caused by spinal cord lesions

    assessed by American Spinal Injury Association (ASIA) scores

    Change from baseline-admission scores ( ASIA ) at 12 months

  • Correlation of clinical observations with blood parameters

    assessed by routinely taken blood tests

    Blood samples will be taken at the time of admission, immediately before the first HBO, immediately after the first HBO, on days 1, 3, 7, 14 , 21 before the respective HBO, and at the 35 days and two months follow-up

Study Arms (2)

test

ACTIVE COMPARATOR

HBO, ASIA score, blood taking

Drug: HBO

control

NO INTERVENTION

ASIA score, blood taking

Interventions

HBODRUG

Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.

Also known as: Hyperbaric oxygenation
test

Eligibility Criteria

Age16 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Test cohort and control cohort:
  • age: 16 to 70 years
  • Traumatic spinal cord injury
  • Initial incomplete or complete (ASIA) sensor/motoric dysfunction
  • Mentally competent patient (no mental disability in history in case of intubated patient)
  • No relevant neuromuscular diseases / neurological deficits before trauma
  • Vertebral column stable, no relevant mechanical compression of spinal cord with our without surgical intervention within 24 hours after the injury;
  • Spinal MRI and CT-scan within first 24 hours
  • Test cohort only:
  • Cardiorespiratory situation allowing safe application of HBO
  • Ability to equalize pressure differences in middle ear confirmed by an ENT (ear, nose, throat) physician or pretherapeutic myringotomy
  • Circumstances allowing HBO-treatment to be started \< 24 hours after the injury

You may not qualify if:

  • Test cohort and control cohort:
  • Morphologically confirmed complete discontinuation of the spinal cord
  • Cardio-respiratory instability
  • Persistent seizure activity in spite of medication
  • Craniocerebral injury exceeding mere commotion
  • Pregnancy
  • Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
  • Simultaneous participation in another interventional study if relevant
  • Test cohort only:
  • Cystic or bullous lung disease, untreated pneumothorax
  • Treatment with doxorubicin in patient´s history

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University Graz

Graz, Austria

Location

MeSH Terms

Interventions

Hyperbaric Oxygenation

Intervention Hierarchy (Ancestors)

Oxygen Inhalation TherapyRespiratory TherapyTherapeutics

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 22, 2017

First Posted

April 5, 2017

Study Start

April 18, 2017

Primary Completion

December 20, 2024

Study Completion

December 20, 2024

Last Updated

May 9, 2025

Record last verified: 2023-03

Locations